Influence of age on half effective dose of remazolam in gastrointestinal endoscopy

Status

Recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2100046746

Enrollment

Unknown

Registered

2021-05-28

Start date

2021-06-01

Completion date

Unknown

Last updated

2022-01-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

aged 18-64 years group:remazolam

aged 65-79 years group:remazolam

aged 80-99 years group:remazolam

Eligibility

Sex/Gender

All

Age

18 Years to 99 Years

Inclusion criteria

Inclusion criteria: 1. The patient aged between 18-99 years; 2. ASA classification is I-III; 3. Body mass index (BMI) 19-27 kg/m^2.

Exclusion criteria

Exclusion criteria: 1. The patient is allergic to remazolam; 2. Long-term use of painkillers; 3. Alcoholism; 4. Nervous system or schizophrenia; 5. Late liver or kidney disease; 6. Sleep apnea syndrome; 7. Uncontrolled hypertension, blood pressure higher than 180/120mmHg; 8. Users of psychotropic drugs.

Design outcomes

Primary

Measure	Time frame
Drug dosage;	—

Secondary

Measure	Time frame
Blood prssure;Heart rate;	—

Countries

China

Contacts

Public ContactChen Haiyan

Department of Anesthesiology, Shanghai Yangpu District Shidong Hospital

chenhaiyan19841984@163.com+86 21 25066782

Outcome results